NeuroPace

NeuroPace, Inc. develops, manufactures and markets implantable devices for treating epilepsy and neurological disorders. It offers implantable components which include the RNS neurostimulator as well as depth and cortical strip leads. The firm's product RNS system is designed for the treatment of medically refractory partial epilepsy includes implantable and external products. The company was founded by Robert Fischell, David Fischell, Tim Fischell, Scott Fischell, Rebecca L. Kuhn, Frank M. Fischer and Martha Morrell on November 19, 1997 and is headquartered in Mountain View, CA.

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Earnings data Q4 2025

Earnings data Q1 2026

NeuroPace reports record revenue in Q1 2023, raises full-year guidance

NeuroPace delivered strong revenue growth in Q1 2023, with a positive outlook for the full year. The company faces challenges in managing operating expenses and sustaining profitability. However, opportunities lie in product distribution, clinical trials, and strategic growth initiatives.

NeuroPace excels in Q2, raises revenue guidance amid strategic growth

NeuroPace's Q2 performance reflects strong growth momentum and improved financial health, supported by strategic partnerships and effective expense management. The company's focus on expanding patient access and optimizing sales operations positions it well for continued success in 2023.

NeuroPace reports robust Q3 earnings, eyes strategic growth opportunities

NeuroPace's Q3 performance reflects strong revenue growth, improved margins, and prudent cost management, positioning the company for sustained success.
While facing challenges in net losses and operating expenses, NeuroPace's operational achievements and financial stability provide a solid foundation for future growth.
By addressing cost structures, leveraging market opportunities, and adapting to evolving market dynamics, NeuroPace can enhance profitability and drive long-term value creation.

NeuroPace reports robust revenue growth and strategic collaborations for 2024

NeuroPace's strong performance in Q4 2023 and full-year results demonstrate growth momentum.
Strategic collaborations and a focus on cost management are key strengths.
Challenges include managing expenses and market dynamics, but growth opportunities are present.
Overall, NeuroPace is well-positioned for revenue growth and transformative impact in 2024.

NeuroPace reports strong Q1 revenue growth and strategic collaborations

NeuroPace's Q1 2024 performance reflects revenue growth, margin improvements, and strategic collaborations.
The company faces challenges in maintaining margins, financial discipline, and closing the treatment gap.
Opportunities lie in expanding therapy access, market growth, and executing the growth strategy.
Overall, NeuroPace is on track to drive revenue through product sales and strategic initiatives.

NeuroPace reports robust Q2 earnings, eyes growth through strategic initiatives

NeuroPace's Q2 2024 performance reflects revenue growth, improved gross margin, and strategic initiatives driving future expansion and market penetration.
While facing challenges in managing operating expenses and maintaining margins, the company's strong cash position and growth strategy present opportunities for sustained growth.
Overall, NeuroPace's focus on innovation, market expansion, and financial prudence positions it well for future success in the neurotechnology sector.

NeuroPace reports robust Q3 earnings, eyes growth in epilepsy market

NeuroPace's Q3 2024 performance reflects solid revenue growth, operational improvements, and strategic focus on innovation and market expansion.
While facing challenges such as operating losses and competitive pressures, the company is well-positioned to leverage growth opportunities in the epilepsy treatment market.
With a strong financial position, effective leadership enhancements, and proactive investor engagement, NeuroPace is poised for continued growth and market success.
Strategic initiatives and upcoming events underscore the company's commitment to driving value for stakeholders and advancing its position in the industry.

NeuroPace reports 22% revenue growth in 2024, eyes market expansion

NeuroPace delivered strong financial performance in 2024, driven by robust revenue growth and strategic product focus. While facing regulatory and growth challenges, the company's balance sheet strength and growth initiatives provide a solid foundation. Opportunities for market expansion and innovation present avenues for sustained growth and competitive positioning.

NeuroPace excels in Q1 with revenue growth and strategic focus

NeuroPace's Q1 performance reflects strong revenue growth and strategic focus on RNS business. While facing financial challenges, the company's initiatives and increased revenue guidance offer growth prospects. Opportunities lie in maintaining operational stability, focusing on high-margin products, and driving clinical development.

NeuroPace achieves record revenue and strategic growth initiatives pay off

NeuroPace delivered a strong financial performance in Q2 2025, with record revenue, improved gross margins, and efficient cost management. The company's strategic strengths lie in successful debt refinancing, compelling clinical trial results, and a focus on innovation and market expansion. Challenges include maintaining growth amidst competition and regulatory uncertainties, while opportunities exist in revenue guidance raise, R&D investments, and market diversification. Overall, NeuroPace's commitment to financial discipline, innovation, and strategic growth initiatives positions it well for future success in the healthcare market.

NeuroPace reports record revenue and positive EBITDA in Q3

NeuroPace's Q3 performance reflects strong revenue growth, operational efficiency, and positive EBITDA, positioning the company for continued success. While facing challenges in market competition and operational management, NeuroPace's strategic initiatives and financial outlook remain promising. With a focus on innovation, market expansion, and clinical advancements, NeuroPace is poised to capitalize on opportunities for growth and leadership in epilepsy neuromodulation.

NeuroPace posts robust Q4 results, eyes growth through AI tools

NeuroPace's Q4 performance reflects strong revenue growth, margin improvement, and positive adjusted EBITDA. The company's strategic initiatives, including product development and market expansion, position it for future success. Addressing challenges and capitalizing on opportunities will be key to sustaining growth and market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NeuroPace, Inc. develops, manufactures, and markets implantable devices for treating epilepsy and neurological disorders. It offers implantable components, which include the RNS neurostimulator as well as depth and cortical strip leads. The firm's RNS System is designed for the treatment of medically refractory partial epilepsy and includes implantable and external products. The company was founded by Rebecca L. Kuhn, Frank M. Fischer on November 19, 1997 and is headquartered in Mountain View, CA.